Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s

Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s
shutterstock_83290528Takeda Pharmaceuticals, which is on the forefront of treating ulcerative colitis and Crohn's disease with the newly launched Entyvio (vedolizumab), will present data concerning the open-label extension phase 3 study of patients receiving Entyvio for a total of two years. The study, GEMINI LTS (Long-Term Safety), will be discussed in three presentations at the 21st United European Gastroenterology Week (UEGW) in Vienna, Austria, and related data will be presented in another abstract. "Ulcerative colitis and Crohn's disease are chronic diseases that can have a serious impact on patients. As physicians, our aim is to help patients achieve and maintain disease remission," said Dr. Severine Vermeire,  of the University Hospitals Leuven in Belgium, in a news article from Drug Discovery & Development Magazine. "Current findings from the long-term extension study add to the evidence bank of vedolizumab as a long-term treatment option for people with ulcerative colitis and Crohn's disease." A preview of findings has already been discussed. The m
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *